Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 491Lung Neoplasms 208Adenocarcinoma of Lung 49Small Cell Lung Carcinoma 34Neoplasms 31Adenocarcinoma, Bronchiolo-Alveolar 25Neoplasm Metastasis 20Breast Neoplasms 20Ovarian Neoplasms 19Colorectal Neoplasms 16Carcinoma 14Squamous Cell Carcinoma of Head and Neck 13Parkinson Disease 4, Autosomal Dominant Lewy Body 13Melanoma 13Carcinoma, Ovarian Epithelial 12Stomach Neoplasms 11Carcinoma, Renal Cell 9Head and Neck Neoplasms 8Respiratory Tract Neoplasms 7Prostatic Neoplasms 7Pancreatic Neoplasms 7Endometrial Neoplasms 7Thoracic Neoplasms 6Pleural Effusion, Malignant 6Lung Diseases 6Esophageal Neoplasms 6Colonic Neoplasms 6Carcinoma, Squamous Cell 6Adenocarcinoma 6Non-Squamous Non-Small Cell Lung Cancer 5

Interventions

Bronchoscopy 2X-Rays 1Taxes 1Radiotherapy 1Radiation 1Paclitaxel 1Carboplatin 1Bevacizumab 1Argon Plasma Coagulation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hemoptysis × Paclitaxel × Thoracic × Clear all
NCT00387374 2013-01-17

Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab

National Cancer Institute (NCI)

Phase 2 Completed
72 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Hemoptysis, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡